Agriculture company Calyxt Inc (NASDAQ: CLXT) announced on Thursday that it plans to crush and produce its high oleic soybean variety through an agreement with American Natural Processors (ANP), a leading provider of innovative non-GMO and organic processing of oils, flours and meals in Cherokee, Iowa.
ANP will crush Calyxt's high-oleic soybean variety and produce its first high oleic consumer soybean oil, which is expected to hit the market in late 2018 / early 2019.
In conjunction, the high-oleic / low-saturated fat oil from Calyxt's new variety of soybeans is designed to eliminate the need for hydrogenation, a process that improves heat stability and shelf life of conventional soybean oil. The process of hydrogenation for conventional soybean oil contributes to the production of trans-fatty acids, which, when consumed, raises low-density lipoprotein, or LDL, and cholesterol levels, as well as contributes to cardiovascular diseases.
Additionally, Calyxt has received a letter from the USDA confirming that its high-oleic soybean variety is non-regulated, as the product contains no foreign DNA.
The US FDA has declared trans fats not generally recognised as safe (GRAS) and human food must no longer contain partially hydrogenated oils by 18 June 2018. The World Health recently unveiled a plan to remove all trans fats worldwide from the food chain by 2023.
Merck completes acquisition of Verona Pharma to expand cardio-pulmonary portfolio
Amgen offers Repatha through AmgenNow direct-to-patient programme
MedHub-AI's AutocathFFR receives national reimbursement approval in Japan
Early, Evidence-Led Cardiovascular Care Strengthened in High-Risk MENA Regions
Corstasis and U.S. Heart and Vascular partner to advance heart failure care with ENBUMYST
Eli Lilly and Company's orforglipron outperforms oral semaglutide in Phase 3 ACHIEVE-3 trial
Merck reports positive Phase 3 results for oral PCSK9 inhibitor enlicitide
Abbott's Navitor TAVI system granted CE Mark for expanded indication
Cereno Scientific receives FDA Fast Track designation for CS1 in pulmonary arterial hypertension
FDA lifts clinical hold on Rocket Pharmaceuticals' RP-A501 Phase 2 Danon disease trial
OptiBiotix signs distribution deal with major weight management company
Novartis to present cardiovascular abstracts portfolio data at ESC Congress in Madrid
LivaNova announces commercial launch of Essenz Perfusion System in China